Skip to main content

Advertisement

Table 1 Baseline Demographic and Medical Characteristics*

From: Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia

  Study Population
  mITT CE
Characteristic Tigecycline (n = 216) Levofloxacin (n = 212) Tigecycline (n = 144) Levofloxacin (n = 136)
Male, n (%) 131 (61) 133 (63) 91 (63) 87 (64)
Race, n (%)     
   White 189 (88) 184 (87) 129 (90) 117 (86)
   Black 2 (<1) 4 (2) - 3 (2)
   Asian 5 (2) 7 (3) 3 (2) 7 (5)
   Other 20 (9) 17 (8) 12 (8) 9 (7)
Mean age ± SD, years (range) 49.9 ± 18.1 (17--92) 49.7 ± 17.4 (18--85) 52.8 ± 16.9 (18--89) 50.4 ± 17.0 (18--85)
Fine Pneumonia Severity Score Index, n (%)     
   I 32 (15) 41 (19) 18 (13) 23 (17)
   II 79 (37) 61 (29) 49 (34) 40 (29)
   III 59 (27) 66 (31) 40 (28) 42 (31)
   IV 44 (20) 42 (20) 35 (24) 30 (22)
   V 2 (<1) 2 (<1) 2 (1) 1 (<1)
Prior antibiotic failure, n (%) 44 (20) 55 (26) 9 (6) 15 (11)
Presence of underlying medical conditions     
   COPD, n (%) 14 (7) 19 (9) 10 (7) 14 (10)
   Diabetes mellitus, n (%) 24 (11) 25 (12) 17 (12) 16 (12)
   Alcohol abuse, n (%) 14 (7) 10 (5) 10 (7) 7 (5)
   Neoplastic disease, n (%) - 2 (<1) - 2 (2)
   Liver disease, n (%) 15 (7) 8 (4) 10 (7) 4 (3)
   Congestive heart disease, n (%) 15 (7) 15 (7) 13 (9) 10 (7)
   Cerebrovascular disease, n (%) 12 (6) 17 (8) 8 (6) 13 (10)
  1. *There were no statistically significant differences between the treatment groups for demographic or baseline medical characteristics for both the mITT and CE populations.